Becton Dickinson's CentroVena One™ Receives Vizient Contract, Enhancing Healthcare Efficiency and Safety

- Becton Dickinson's BD® CentroVena One™ received an Innovative Technology contract from Vizient for streamlining central line insertions.
- The CentroVena One™ reduces steps by 30% and procedure time by 50%, enhancing workflow and patient safety.
- BD's commitment to innovation attracts investor interest, positioning the company favorably in the medical technology sector.
Becton Dickinson & Company (BDX) continues to strengthen its position in the medical technology arena, having recently received an Innovative Technology contract from Vizient for its BD® CentroVena One™ Insertion System. This recognition follows a careful assessment by healthcare professionals, underscoring the system's potential to significantly enhance healthcare delivery. The CentroVena One™ stands out for its all-in-one design, which addresses clinical needs by streamlining the central line insertion process that often faces complexities and procedural errors. With its emphasis on improving efficiency, the system is poised to transform the traditional approach to central line insertion in hospitals, making it a vital tool for medical professionals.
Revolutionizing Central Line Insertion
The introduction of the CentroVena One™ offers considerable benefits over traditional methods, with studies published in The Journal of Emergency Medicine indicating that it reduces the number of steps required by 30% and minimizes the maximum procedure time by 50%. This efficiency not only enhances the procedural workflow but also bolsters patient safety, as the system is designed with features that significantly mitigate the risks associated with central line placements, such as contamination and other complications. Eric Borin, president of Medication Delivery Solutions at BD, emphasizes that the intention behind this innovation is to fundamentally change how central line insertions are carried out to promote better outcomes in patient care.
Endorsement from Vizient
Vizient's decision to award this Innovative Technology contract is indicative of the product's high impact on the healthcare sector. Serving a widespread network of healthcare providers with a robust annual purchasing volume, Vizient plays a pivotal role in evaluating and endorsing innovative products that promise to refine healthcare delivery. BD’s commitment to introducing cutting-edge solutions like the CentroVena One™ aligns closely with the growing demand for safer, more efficient medical technologies, reinforcing its position as a frontrunner in the industry.
Related Cashu News

Merit Medical Systems Launches Employee Stock Ownership Plan to Boost Engagement and Stability
Merit Medical Systems (Ticker: MMSI) recently takes a significant step in enhancing its employee engagement and ownership structure with the launch of a new Employee Stock Ownership Plan (ESOP). The c…

Brookdale Senior Living launches second season of educational podcast "The Grey Take.
Brookdale Senior Living (Ticker: BKD) launches the second season of its popular podcast, "The Grey Take," which serves as a valuable resource for families exploring senior living options. The podcast…

Molina Healthcare Gains Momentum with Increased Risk Adjustment Payments and Positive Revenue Outlook
Molina Healthcare (Ticker: MOH) is making significant strides in its revenue outlook due to recently released risk adjustment figures from the Centers for Medicare & Medicaid Services (CMS). These upd…

Align Technology Faces Antitrust Investigation by European Commission Over Competitive Practices
Align Technology Inc. (Ticker: ALGN) faces a formal antitrust investigation from the European Commission, marking a significant development in the medical devices sector. This inquiry arises from a co…

